We are live on ! Find out more
AQST icon

Aquestive Therapeutics

49 hedge funds and large institutions have $100M invested in Aquestive Therapeutics in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

36% more funds holding

Funds holding: 36 → 49 (+13)

11% more capital inflows, than outflows

Capital inflows: $5.02M | Capital outflows: $4.53M

0.11% more ownership

Funds ownership: 57.62% → 57.72% (+0.11%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
49
Holders Change
+13
Holders Change %
+36.11%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
14
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AQST Hedge Fund Activity: Q1 2019 in Review

49 of the 4,635 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2019, worth a combined $100M — up 10% from $90.5M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new AQST positions and 6 closed out — a net gain of 13 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $1.12M. The largest seller was AllianceBernstein, cutting an estimated $2.35M.

  • 49 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2019, up from 36 in Q4 2018.
  • Funds reported $100M of Aquestive Therapeutics stock for Q1 2019, up 10% quarter-over-quarter.
  • 19 funds opened new Aquestive Therapeutics positions in Q1 2019 and 6 closed out, a net change of +13 holders.
  • The largest Aquestive Therapeutics buyer in Q1 2019 was BlackRock, an estimated $1.12M added.
  • The largest Aquestive Therapeutics seller in Q1 2019 was AllianceBernstein, an estimated $2.35M sold.

Based on aggregated 13F filings for Q1 2019.